Business Wire India

Nemaura Pharma secures funding to advance its Micro-Patch™ solid dose microneedle system for a hormone Biologic

  • Posted on: 9 February 2017
  • By: PharmaTutor News

UK biotech company Nemaura Pharma has announced a commitment from private investors of up to £5m for the development of a hormone Biologic using its Micro-Patch™ solid dose delivery platform. The fast-growing company has made significant progress in the reformulation of liquid vaccines administered through the skin using its solid dose delivery system. The funding is being used to accelerate Nemaura’s commercial research and development of clinical programmes to prepare the drug-device combination for market.

ICON issues financial guidance for full year 2017

  • Posted on: 10 January 2017
  • By: PharmaTutor News

DUBLIN a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, announced its financial guidance for the year ended December 31, 2017. For the full year 2017 revenue will be in the range of $1,700 - $1,750 million, representing growth of 2 - 5% and earnings per share will be in the range of $5.00 - $5.20, representing growth of 6 - 11%.

Takeda to Acquire ARIAD Pharmaceuticals, Inc

  • Posted on: 10 January 2017
  • By: PharmaTutor News

Takeda Pharmaceutical Company Limited announced that they have entered into a definitive agreement under which Takeda will acquire all of the outstanding shares in ARIAD for $24.00 per share in cash, or an enterprise value of approximately $5.2 billion. The transaction has been approved unanimously by the boards of directors of both companies, and is expected to close by the end of February 2017, subject to required regulatory approvals and other customary closing conditions. Sarissa Capital, the holder of 6.6% of ARIAD’s common shares, as well as each of the members of ARIAD’s Board of Directors have agreed to tender their shares to Takeda pursuant to the offer

Self-regulation Code of Conduct for the E-pharmacy Sector in the Interest of Consumer

  • Posted on: 21 November 2016
  • By: PharmaTutor News

The Federation of Indian Chambers of Commerce and Industry (FICCI) - an apex business organization - announced the launch of Self-regulation Code of Conduct  for the E-pharmacy sector in the presence of Government dignitaries and the concerned stakeholders.

Morepen Labs Reports 118 Per Cent Jump in Net Profits for the Q2 of FY 2016-17, Backed by a Good Performance in API and Dr. Morepen Health Basket

  • Posted on: 14 November 2016
  • By: PharmaTutor News

Major contributories to company’s spectacular performance in Q2 include its top selling bulk drugs Montelukast (an anti-asthmatic), Atorvastatin (statin) and Rosuvastatin (another statin drug), which registered a jump of 46 per cent, 33 per cent and 203 per cent respectively in their sales revenues. This apart, consumer health products promoted under Dr. Morepen umbrella brand i.e. Home Diagnostics, OTC (Over the Counter) products and Formulations also recorded excellent sales nos. for the quarter under consideration.

Stop Buying Medicines if You are Not Going to Have it as Prescribed

  • Posted on: 14 November 2016
  • By: PharmaTutor News

How often have you said this or heard people saying it? We forget many things in our daily lives, but there is a difference when we forget to take our prescribed medicines. If you missed yesterday’s medicines, you can’t take them today – the damage has already happened in your body. According to the World Health Organization, “Approximately 50% of patients do not take their medications as prescribed.” This can lead to significant increase in hospitalization, treatment failure and even death. As per studies 2.5 times increased risk of hospitalization for patients with diabetes.

Medical Device Industry urges Ministry of Health & Family Welfare to expedite PMO's Decisions on regulatory reforms for the sector

  • Posted on: 18 October 2016
  • By: PharmaTutor News

AiMeD, the apex body of Indian medical device manufacturers, has urged the Ministry of Health and Family Welfare for speedy implementation of the decision taken three months ago by the Prime Minister’s Office to initiate wide ranging regulatory reforms for medical device sector in order to boost domestic manufacturing and investment in the sector as well as to ensure enhanced healthcare security for common Indian citizens.

Jubilant DraxImage Receives FDA Approval for RUBY-FILL Rubidium 82 Generator and Elution System

  • Posted on: 4 October 2016
  • By: PharmaTutor News

Jubilant Pharma Ltd, announced that the U.S. Food and Drug Administration has approved RUBY-FILL®, an innovative technology for Positron Emission Tomography (PET) myocardial perfusion imaging (MPI). Comprised of a Rubidium-82 (Rb-82) Generator and precedent setting Elution System, RUBY-FILL® is used to produce a personalized patient dose of Rubidium Rb 82 chloride used to evaluate regional myocardial perfusion in adult patients with suspected or existing coronary artery disease (CAD) which is an important component of diagnosing CAD.

Pages